G1 Therapeutics (GTHX) Misses Q3 EPS by 1c; Offers FY23 COSELA Sales Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to G1 Therapeutics (GTHX) Misses Q3 EPS by 1c; Offers FY23 COSELA Sales Guidance

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

November 1, 2023 6:30 AM EDT

- Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter -

- Confirmed Expectation of Interim Overall Survival (OS) Analysis for Pivotal Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 -

- Reiterated Expectation of Initial OS Results from Phase 2 Trial of Trilaciclib in Combination with an Antibody-Drug Conjugate (ADC) in the First Quarter of 2024 -

- COSELA Recommended in Updated American Society of Clinical Oncology (ASCO) Small Cell Lung Cancer... More